Cystathionine β-synthase enzyme for treating homocystinuria
Recombinantly engineered CBS variants, particularly rhCBSΔC and C15S, effectively lower serum homocysteine and increase cystathionine and cysteine levels, addressing the limitations of current treatments for homocystinuria and improving patient compliance and health outcomes.
Patent Information
- Application Number
- JP2023028266
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2013-03-14
- Filing Date
- 2023-02-27
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2034-01-29
AI Technical Summary
Current treatments for homocystinuria, such as vitamin B6 supplementation, Met-restricted diets, and betaine supplementation, fail to effectively reduce serum homocysteine levels and do not increase downstream metabolites like cystathionine and cysteine, leading to inadequate compliance and severe health complications.
Development of recombinantly engineered cystathionine β-synthase (CBS) variants, specifically truncated and PEGylated forms like rhCBSΔC and C15S, which are administered to lower serum homocysteine levels and increase cystathionine and cysteine production, allowing for a less restrictive diet and improved clinical outcomes.
The engineered CBS variants significantly reduce serum homocysteine levels, normalize downstream metabolites, and improve clinical outcomes by reducing morbidity and mortality associated with homocystinuria, while allowing for a more manageable dietary regimen.
Smart Images

Figure 0007580822000012 
Figure 0007580822000013 
Figure 0007580822000014
Abstract
Description
[Technical field]
[0001] (Citation of Related Application) This application claims the benefit of U.S. Provisional Application No. 61 / 758,138, filed January 29, 2013, and U.S. Application No. 13 / 803,804, filed March 14, 2013, the disclosures of each of which are incorporated by reference.
[0002] FIELD OF THEINVENTION The present invention generally relates to compositions suitable for enzyme replacement therapy, comprising a form of human cystathionine β-synthase (CBS) that can significantly reduce serum homocysteine (Hcy) concentration and increase the production of downstream metabolites such as cystathionine and cysteine. Such compositions can be used for the treatment of conditions or diseases such as homocystinuria and homocysteine remethylation disorders. [Background technology]
[0003] BACKGROUND OF THEINVENTION CBS is a central enzyme in the sulfur-containing substituent transfer pathway and plays an essential role in homocysteine (Hcy) metabolism in eukaryotes (Mudd et al., 2001, in The Journal of Metabolic and Molecular Bases of Inherited Disease, 8 Ed., pp. 2007-2056, McGraw-Hill, New York). The CBS enzyme catalyzes the pyridoxal-5'-phosphate (PLP; vitamin B6)-dependent condensation of serine and homocysteine to form cystathionine, which is then used to generate cysteine by another PLP-dependent enzyme, cystathionine γ-lyase. When CBS activity is dramatically reduced or absent as a result of certain genetic mutations, Hcy accumulates in tissues and blood. In mammalian cells that possess a sulfur-containing substituent transfer pathway, CBS occupies an important regulatory position between the remethylation of Hcy to methionine or another use in the biosynthesis of cysteine.
[0004] In healthy normal individuals, the CBS-mediated conversion of Hcy to cystathionine is the rate-limiting intermediate step in the metabolism of methionine (Met) to cysteine (Cys). Vitamin B6 is an essential coenzyme for this process. In individuals with certain genetic mutations in the CBS enzyme, the conversion of Hcy to cystathionine is slow or absent, resulting in elevated serum concentrations of the enzyme substrate (Hcy) and a corresponding decrease in serum concentrations of its enzyme product (cystathionine; Cth). The clinical condition of elevated serum levels of Hcy, and its associated excretion in the urine, is collectively known as homocystinuria.
[0005] Estimates of the prevalence of homocystinuria vary widely. Newborn screening data and clinical confirmation yield a range of 1:200,000 to 1:335,000 live births (Mudd et al., 2001). Recent evidence from newborn DNA screening studies in Denmark, Germany, Norway, and the Czech Republic has found that the true incidence may be as high as about 1:6,000 (Gaustadnes et al., 1999, N Engl J Med. 1340:1513; Linnebank et al., 2001, Thromb Haemost. 85:986; Refsum et al., 2004, Clin. Chem. 50:3; Sokolova et al., 2001, Hum Mutat.18:548). Furthermore, recent studies have shown that CBS deficiency homocystinuria (CBSDH) individuals may suffer from either psychiatric or cardiovascular complications, but are currently undiagnosed due to the absence of characteristic connective tissue defects that typically aid in diagnosis (Li and Stewart, 1999, Pathol. 31:221; Linnebank et al., 2003, J. Inherited Metabol. Dis. 26: 509; Maclean et al., 2002, Hum Mutat. 19:641). The major health problems associated with CBSDH include: cardiovascular disease with predisposition to thrombosis, which results in high mortality in untreated and partially treated individuals; connective tissue problems affecting the visual system with progressive myopia and ectopia lentis; connective tissue problems affecting the skeleton, characterized by Marfan habitus, osteoporosis, and scoliosis; and central nervous system problems, including mental retardation and seizures.
[0006] The therapeutic resolution of CBS-associated homocystinuria depends on the type of mutation present in the CBS gene. Approximately 160 pathogenic mutations in the CBS gene have been identified in humans to date. There is a functional trichotomy in the nature of the pathogenic mutations associated with CBSDH. One group of mutations is classified as "pyridoxine-responsive," in which CBS enzyme function can be restored by high-dose vitamin B6 treatment. This treatment can be effective, but does not always alleviate the pathological events in these individuals, some of which may even occur in these individuals over time. The second group of functional mutations is represented by "C-terminal CBS mutants," which are defective in their ability to respond to posttranslational upregulation by S-adenosylmethionine. Individuals with this class of mutations usually lack mental retardation and connective tissue aspects of the phenotype. This class is detected after measurement of plasma Hcy levels following idiopathic thrombotic events before the age of 40 (Maclean et al., 2002, Hum Mutat. 19: 641-55). The final group of CBSDH mutations is "classical homocystinuria," which represents the most severe form of the disease. For these latter two groups of individuals, vitamin B6 treatment, in isolation, does not effectively lower serum Hcy levels.
[0007] The pathophysiology of homozygous CBS deficiency is undoubtedly complex, but there is consensus that the fundamental instigator of end-organ injury is extremely elevated serum Hcy. The toxicity of significantly elevated blood and tissue concentrations of Hcy may occur as a result of molecular reactivity and biological effects deriving from Hcy itself or from its metabolites (e.g., Hcy-thiolactone), which affect many biological processes (Jakubowski et al., 2008, FASEB J 22: 4071-6). Abnormalities in chronic platelet aggregation, altered vascular parameters, and endothelial dysfunction have all been described in individuals with homocystinuria.
[0008] Currently, three treatment options exist for the treatment of CBSDH: 1) an increase in residual CBS activity using pharmacological doses of vitamin B6 in vitamin B6-responsive individuals; 2) lowering serum Hcy by a diet that severely restricts Met intake; and 3) Detoxification through betaine-mediated conversion of Hcy to Met, thus reducing serum Hcy concentrations.
[0009] Each of these three treatments aims to lower serum Hcy concentrations. Standard treatment for individuals with vitamin B6-unresponsive CBSDH consists of a metabolic formula and a Met-restricted diet supplemented with Cys, which is a conditionally essential amino acid in this condition. Consumption of meat, dairy products, and other foods high in natural protein is prohibited. Daily intake of an unpalatable synthetic metabolic formula containing amino acids and micronutrients is required to prevent secondary malnutrition. Betaine (brand name: CYSTADANE) TM Supplementation with betaine (also known as trimethylglycine) is also the standard of care. Betaine serves as the methyl donor for the remethylation of Hcy to Met catalyzed by betaine-homocysteine methyltransferase in the liver (Wilcken et al., 1983, N Engl J Med 309:, (8), 448-53). Compliance with the diet is generally poor, even in optimally cared for and resourced medical centers, and this noncompliance has significant implications for the development of life-threatening complications of homocystinuria.
[0010] The evidence presented in the above sections can be summarised in the following points: · Untreated homocystinuria has a high rate of complications in the vasculature, connective tissue, and central nervous system. Treatments that lower serum Hcy (e.g. severe Met-restricted diets and betaine) if adequately implemented reduce associated clinical problems. Improvement in cognitive performance requires initiation of treatment in infancy. Compliance with the diet is uniformly poor. In individuals beginning treatment in the neonatal period, loss of compliance occurs during adolescence. In individuals beginning treatment after the neonatal period, compliance is downright poor at all ages. The extreme difficulties of current treatment approaches are most readily apparent in individuals who experience life-threatening symptoms that could be prevented by diet, and yet fail to adhere to this treatment. Failure to comply with the diet can result in increased serum Hcy, recurrence of vascular and connective tissue complications, including fatal and incapacitating events, and risk of serious side effects, e.g., cerebral edema (due to excessive serum Met concentrations) or severe malnutrition (due to lack of essential amino acids). The most effective therapeutic strategy is to increase enzyme activity, as is evident when giving pyridoxine to vitamin B6-responsive homocystinuria. This strategy is not possible in vitamin B6-nonresponsive individuals, due to their mutational status, and increased enzyme activity in these individuals depends on the delivery of exogenous enzymes, i.e., enzyme replacement therapy (ERT), a strategy that has never been attempted to treat homocystinuria. Of the three current treatment strategies with demonstrated efficacy: (1) increasing enzyme activity with pyridoxine in vitamin B6-responsive individuals; (2) reducing accumulated metabolites by dietary Met restriction; and (3) detoxification through the enzyme activity of betaine-homocysteine methyltransferase in betaine treatment, all share a common goal of lowering plasma total Hcy (Walter, et al., 1998, Eur J Pediatr 157(Suppl 2):S71-6).
[0011] Furthermore, for all current treatment strategies used in human patients (except for B6 supplementation, which is only suitable for a subset of homocystinuria), lowering of homocysteine is not accompanied by an increase in Cth or Cys. Because it has not yet been established that excess Hcy, rather than a deficiency of downstream metabolites, is the cause of clinical symptoms, current therapies limited to lowering homocysteine may be insufficient to provide robust and effective treatment options. [Prior art documents] [Non-patent literature]
[0012] [Non-Patent Document 1] Gaustadnes et al., N Engl J Med. (1999)1340:1513 [Non-Patent Document 2] Linnebank et al., Thromb Haemost. (2001) 85:986 [Non-Patent Document 3] Refsum et al., Clin. Chem. (2004) 50:3 [Non-Patent Document 4] Sokolova et al., Hum Mutat. (2001) 18:548 Summary of the Invention [Problem to be solved by the invention]
[0013] Thus, there remains a need in the art for more effective treatment strategies for individuals with homocystinuria. [Means for solving the problem]
[0014] Summary of the Invention As shown herein, the present invention provides compositions, particularly compositions and methods, for specifically lowering serum Hcy in individuals with homocystinuria.Also provided are compositions, particularly pharmaceutical compositions, for restoring substantially normal levels of metabolites, including but not limited to methionine, such as cysteine and cystathionine.As described more specifically herein, reagents and methods are provided for enzyme replacement therapy (ERT) of homocystinuria, in which modified forms of native enzymes are recombinantly engineered to improve their pharmaceutical acceptability, particularly by providing improved stability, activity, and medical utility in vivo.
[0015] In a first aspect, the invention provides an isolated CBS polypeptide comprising SEQ ID NO:02, wherein the isolated CBS polypeptide comprises a chemical modification and is an engineered truncation of the full-length human CBS protein at the amino terminus, the carboxyl terminus, or both the amino and carboxyl termini. In one embodiment, the invention provides an engineered variant of human CBS constituting a recombinant human CBS, wherein the C-terminal regulatory region has been removed (e.g., rhCBSΔC, which is truncated by 138 residues at the carboxyl terminus and comprises amino acids 1-413 of the 551 amino acids of the full-length protein) (SEQ ID NO:3). In some embodiments, the species of rhCBSΔC is mutated, and in a preferred embodiment, the truncated mutant CBS is rhCBSΔC-C15S (or abbreviated as "C15S," which is truncated by 138 residues at the carboxyl terminus; same as rhCBSΔC) (SEQ ID NO:13), wherein the cysteine residue at position 15 in the CBS amino acid sequence has been changed to a serine. In certain embodiments, disclosed herein include species of truncated recombinant human CBS that are chemically modified, particularly by the covalent attachment of a polyethylene glycol (PEG) moiety to C-terminal truncated recombinant human CBS (particularly rhCBSΔC). These PEGylated species are referred to as PEG-rhCBSΔC or PEG-C15S, respectively. These compositions (modified recombinant enzymes) and methods useful, particularly therapeutically useful, as shown herein, allow individuals with homocystinuria to enjoy a very less restrictive diet (e.g., ingesting 2 g or more of protein per kg daily) and have significantly reduced Hcy plasma levels and substantially normalized metabolite levels, including but not limited to methionine (e.g., cysteine and cystathionine), resulting in long-term clinical improvement.
[0016] The present invention advantageously allows individuals to achieve good control of serum Hcy levels without the use of extremely restrictive diets that have unacceptable non-compliance rates. The use of the truncated species, particularly the mutated (especially the C15S mutant), PEGylated, or mutated and PEGylated species, may advantageously be accompanied by improved metabolism in individuals, which may result in improved clinical outcomes, as reflected in reduced morbidity and mortality, particularly in association with significantly reduced serum Hcy concentrations.
[0017] As disclosed herein, the C15S mutant human CBS species advantageously adopts a conformation that significantly increases in vivo medical usefulness (e.g., no detectable levels of aggregation).The C15S mutant human CBS species also exhibits highly reproducible expression, purification, and PEGylation patterns, and the C15S mutation reduces the formation of aggregates, improving yields by improving recovery, allowing for more consistent and reproducible PEGylation.These aspects may also be useful in terms of quality, particularly related to the process, prior to in vivo usefulness.
[0018] As disclosed herein, the PEGylated species advantageously have an increased size compared to non-PEGylated truncated variants, particularly the rhCBSΔC or C15S species, where the PEGylated species have reduced or delayed clearance. Furthermore, chemical modification with PEG masks potential immunogenic epitopes on the surface of the protein, preventing proteolytic enzymes from accessing the protein. PEGylation also advantageously alters the physicochemical properties of the rhCBSΔC protein, thus modifying its biodistribution, stability and solubility, without significantly reducing its efficacy.
[0019] These and other features and advantages of the present invention will be more fully understood from the following detailed description of the invention, taken in conjunction with the appended claims, which are noted to be defined by the description therein, and not by any specific consideration of the features and advantages set forth in the description of the invention.
[0020] The following detailed description of the embodiments of the invention can be best understood when read in conjunction with the following drawings. For example, the present invention provides the following: (Item 1) An isolated cystathionine-β-synthase (CBS) polypeptide comprising SEQ ID NO:02 or a homolog, variant or mutant thereof, wherein the isolated CBS polypeptide has been chemically modified and comprises a truncation of a full-length human CBS protein at the amino terminus, the carboxyl terminus, or both the amino terminus and the carboxyl terminus. (Item 2) 2. The isolated CBS polypeptide of claim 1, wherein the isolated CBS polypeptide is an engineered truncation that is a deletion of C-terminal residues 383-551, 397-551, 414-551, 442-551, 489-551, 497-551, 524-551, 534-551, or 544-551. (Item 3) 3. The isolated CBS polypeptide of claim 2, wherein the isolated CBS polypeptide comprises a deletion of C-terminal residues 414 to 551. (Item 4) 4. The isolated CBS polypeptide according to any of items 1 to 3, wherein the isolated CBS polypeptide is an engineered truncation selected from a deletion of N-terminal residues 2 to 39 or 1 to 70. (Item 5) 2. The isolated CBS polypeptide of claim 1, wherein the isolated CBS polypeptide comprises a cysteine to serine change at amino acid position 15. (Item 6) 6. The isolated CBS polypeptide of claim 5, wherein the isolated CBS polypeptide comprising a cysteine to serine change at amino acid position 15 is an engineered truncation selected from a deletion of C-terminal residues 383-551, 397-551, 414-551, 442-551, 489-551, 497-551, 524-551, 534-551 or 544-551. (Item 7) 7. The isolated CBS polypeptide of claim 6, wherein the isolated CBS polypeptide comprising a cysteine to serine change at amino acid position 15 also comprises a deletion of C-terminal residues 414 to 551 (SEQ ID NO: 13). (Item 8) 1. An isolated CBS polypeptide comprising SEQ ID NO:02 or a homolog thereof, wherein said isolated CBS polypeptide comprises a cysteine to serine change at amino acid position 15, said isolated CBS polypeptide being chemically modified. (Item 9) 9. The isolated CBS polypeptide according to any one of items 1 to 8, wherein the CBS polypeptide is covalently linked to one or more polyethylene glycol molecules. (Item 10) 10. The isolated CBS polypeptide of claim 9, wherein the polyethylene glycol molecule is selected from unbranched and branched polyethylene glycol. (Item 11) 11. The isolated CBS polypeptide of claim 10, wherein the polyethylene glycol molecule has a molecular weight of 2000 daltons or more. (Item 12) 12. The isolated CBS polypeptide according to item 11, wherein the polyethylene glycol molecule has a molecular weight in the range of 5 to 80 kD. (Item 13) 12. The isolated CBS polypeptide according to item 11, wherein the polyethylene glycol molecule preferably has a molecular weight in the range of 10 to 40 kD. (Item 14) 12. The isolated CBS polypeptide of claim 11, wherein the polyethylene glycol molecule is ME-200MA0B, ME-020MA, ME-400MA, GL2-400MA, GL4-400MA, GL2-800MA, ME-050GS, ME-200GS, ME-200AL or MEPA-20T. (Item 15) 15. The isolated CBS polypeptide according to any one of items 8 to 14, wherein the polyethylene glycol molecule is attached to the CBS by a linking group selected from the group consisting of NHS, amines, and aldehydes of monoaldehydes, monoesters of monoacids, monoamines, monothiols, monodisulfides, monobromophenyl carbonates, monochlorophenyl carbonates, monofluorophenyl carbonates, mononitrophenyl carbonates, monocarbonylimidazoles, monohydrazides, monoiodoacetamides, monomaleimides, monoorthopyridyl disulfides, monooximes, monophenylglyoxals, monothiazolidine-2-thiones, monothioesters, monotriazines, and monovinyl sulfones. (Item 16) 16. The isolated CBS polypeptide of any of items 1 to 15, wherein the CBS polypeptide is active in the absence of S-adenosylmethionine (AdoMet). (Item 17) 17. A pharmaceutical composition comprising an isolated CBS polypeptide according to any one of items 1 to 16, comprising a therapeutically effective amount of said polypeptide, a homologue, variant or mutant thereof and a pharma- ceutically acceptable carrier, diluent or excipient. (Item 18) 18. The pharmaceutical composition according to any of items 1 to 17, which retains 70% or more of the initial activity of the composition administered after 24 hours. (Item 19) 18. The pharmaceutical composition of item 17, which retains 70% or more of the initial activity of the composition administered after 24 hours. (Item 20) 20. The pharmaceutical composition according to any of items 17 to 19, wherein the CBS polypeptide is covalently bound to one or more polyethylene glycol molecules. (Item 21) 21. A method for reducing homocysteine in an individual in need thereof comprising administration of an isolated CBS polypeptide according to any of items 1 to 20. (Item 22) 22. The method of claim 21, wherein the isolated CBS polypeptide is administered by implantable osmotic pump, intravenous injection, subcutaneous injection, or intraperitoneal injection. (Item 23) 22. The method of claim 21, wherein the isolated CBS polypeptide is administered by subcutaneous injection. (Item 24) 22. The method of claim 21, wherein the isolated CBS polypeptide is administered by an implantable osmotic pump. (Item 25) 25. The method of any of items 21 to 24, wherein the isolated CBS polypeptide comprises a constant amount of the isolated CBS polypeptide, wherein 0.1 mg / kg to 20 mg / kg is administered. (Item 26) 21. A method for elevating cystathionine or cysteine in an individual in need thereof, the method comprising administration of an isolated CBS polypeptide according to any of items 1 to 20. (Item 27) 27. The method of claim 26, further comprising administration of one or more of an anticoagulant, a statin, or a mildly protein restricted diet, anethole dithiolethione, or betaine. (Item 28) 27. The method of claim 26, wherein the isolated CBS polypeptide is administered by implantable osmotic pump, intravenous injection, subcutaneous injection, or intraperitoneal injection. (Item 29) 27. The method of claim 26, wherein the isolated CBS polypeptide is administered by intravenous injection. (Item 30) 27. The method of claim 26, wherein the isolated CBS polypeptide is administered by an osmotic pump. (Item 31) 31. The method of any of items 26 to 30, wherein the isolated CBS polypeptide comprises a quantity of the isolated CBS polypeptide, wherein up to 20 mg / kg is administered to an individual in need thereof. (Item 32) 21. A method for treating or ameliorating a disease, disorder, or condition associated with elevated homocysteine, methionine, S-adenosylmethionine and S-adenosylhomocysteine, and low cystathionine and cysteine levels, comprising administering to an individual in need of treatment or amelioration a pharma- tically effective amount of an isolated CBS polypeptide according to any one of items 1 to 20. (Item 33) 33. The method of claim 32, wherein the disease, disorder, or condition associated with elevated homocysteine is mental retardation, osteoporosis, ectopia lentis, kyphoscoliosis, stroke, myocardial infarction, or pulmonary embolism. (Item 34) 33. The method of claim 32, wherein the isolated CBS polypeptide comprises a quantity of the isolated CBS polypeptide, wherein up to 20 mg / kg is administered by parenteral injection. (Item 35) 33. The method of claim 32, wherein the isolated CBS polypeptide comprises a quantity of the isolated CBS polypeptide, wherein up to 20 mg / kg is administered by an implantable osmotic pump. (Item 36) 33. The method of claim 32, further comprising administration of anetholedithiolthione or betaine. (Item 37) 33. The method according to item 32, wherein betaine is administered twice a day. (Item 38) 21. A method for preventing a disease, disorder or condition associated with elevated homocysteine, the method comprising administering to an individual in need thereof a pharma- tically effective amount of an isolated CBS polypeptide according to any one of items 1 to 20. (Item 39) 39. The method of claim 38, wherein the disease, disorder, or condition associated with elevated homocysteine is mental retardation, osteoporosis, ectopia lentis, kyphoscoliosis, stroke, myocardial infarction, or pulmonary embolism. (Item 40) 39. The method of claim 38, wherein the isolated CBS polypeptide comprises a quantity of the isolated CBS polypeptide, wherein up to 20 mg / kg is administered to an individual in need thereof. (Item 41) 39. The method of claim 38, further comprising administration of anetholedithiolthione or betaine. (Item 42) 39. The method according to item 38, wherein betaine administration is performed twice a day. (Item 43) 21. Use of an isolated CBS polypeptide according to any of items 1 to 20 for the manufacture of a medicament for treating or ameliorating a disease, disorder or condition associated with elevated homocysteine. (Item 44) 44. The use according to item 43, wherein the disease, disorder or condition associated with elevated homocysteine is mental retardation, osteoporosis, ectopia lentis, kyphoscoliosis, stroke, myocardial infarction or pulmonary embolism. (Item 45) Item 44. The use according to item 43, wherein the medicament further comprises anetholedithiolthione or betaine. (Item 46) 44. The use according to item 43, further comprising restricting the diet to a mildly protein restricted diet. [Brief description of the drawings]
[0021] [Figure 1-1]FIG. 1 illustrates experimental evidence of enhanced plasma enzyme retention time in vivo after rhCBSΔC PEGylation. FIG. 1 provides pharmacokinetic profiles of rhCBSΔC and PEGylated rhCBSΔC after a single dose and evidence of their stability in vivo. FIG. 1a is a bar graph showing the results of an experiment in which C57BL / 6J mice were injected with 5 mg / kg body weight of human truncated CBS (rhCBSΔC) via intraperitoneal (IP), intravascular (IV) or subcutaneous (SQ) routes. Two experimental groups (labeled 1 and 2) of 5 mice each were used for each injection route (n=30 total). For each injection route, blood was collected from group 1 at 0, 1, 8 and 24 hours post-injection, and from group 2 at 1, 4, 10 and 48 hours post-injection. Plasma was analyzed for CBS activity using a radioactivity assay (as described in Example 1). Figure 1b is a photograph of the results of Western blot analysis of CBS in plasma from two representative mice of each group as described in Figure 1a, tracking CBS clearance from the circulation. After SDS-PAGE separation of CBS on a 12% gel and Western blotting to a polyvinylidene difluoride (PVDF) membrane, the membrane was probed with rabbit polyclonal anti-hCBS antibody followed by a secondary anti-rabbit antibody conjugated to horseradish peroxidase, and the bands were visualized with SuperSignal West Pico Chemiluminescent Substrate (Pierce cat# 34077). Figure 1c is a bar graph showing the results of an experiment in which mice were injected with 5 mg / kg body weight of ME020MA- or GL4-400MA-PEGylated rhCBSΔC or non-PEGylated rhCBSΔC via the SQ route. ME020MA represents rhCBSΔC enzyme PEGylated with ME020MA, GL4-400MA represents rhCBSΔC enzyme PEGylated with GL4-400MA, and rhCBSΔC represents unmodified rhCBSΔC enzyme. Each treatment arm consisted of two groups of five mice (total of 30 mice) that were bled at the indicated time points as described in Example 2 and shown in Figure 1A. Plasma was analyzed for CBS activity using a radioactivity assay. [Figure 1-2] FIG. 1 illustrates experimental evidence of enhanced plasma enzyme retention time in vivo after rhCBSΔC PEGylation. FIG. 1 provides pharmacokinetic profiles of rhCBSΔC and PEGylated rhCBSΔC after a single dose and evidence of their stability in vivo. FIG. 1a is a bar graph showing the results of an experiment in which C57BL / 6J mice were injected with 5 mg / kg body weight of human truncated CBS (rhCBSΔC) via intraperitoneal (IP), intravascular (IV) or subcutaneous (SQ) routes. Two experimental groups (labeled 1 and 2) of 5 mice each were used for each injection route (n=30 total). For each injection route, blood was collected from group 1 at 0, 1, 8 and 24 hours post-injection, and from group 2 at 1, 4, 10 and 48 hours post-injection. Plasma was analyzed for CBS activity using a radioactivity assay (as described in Example 1). Figure 1b is a photograph of the results of Western blot analysis of CBS in plasma from two representative mice of each group as described in Figure 1a, tracking CBS clearance from the circulation. After SDS-PAGE separation of CBS on a 12% gel and Western blotting to a polyvinylidene difluoride (PVDF) membrane, the membrane was probed with rabbit polyclonal anti-hCBS antibody followed by a secondary anti-rabbit antibody conjugated to horseradish peroxidase, and the bands were visualized with SuperSignal West Pico Chemiluminescent Substrate (Pierce cat# 34077). Figure 1c is a bar graph showing the results of an experiment in which mice were injected with 5 mg / kg body weight of ME020MA- or GL4-400MA-PEGylated rhCBSΔC or non-PEGylated rhCBSΔC via the SQ route. ME020MA represents rhCBSΔC enzyme PEGylated with ME020MA, GL4-400MA represents rhCBSΔC enzyme PEGylated with GL4-400MA, and rhCBSΔC represents unmodified rhCBSΔC enzyme. Each treatment arm consisted of two groups of five mice (total of 30 mice) that were bled at the indicated time points as described in Example 2 and shown in Figure 1A. Plasma was analyzed for CBS activity using a radioactivity assay. [Diagram 2] FIG. 2 is a bar graph showing that a stable level of CBS activity is achieved after repeated SQ administration. Injection with PEGylated rhCBSΔC showed increased CBS activity in vivo, whereas injection with non-PEGylated rhCBSΔC did not. GL4-400MA represents GL4-400MA PEGylated rhCBSΔC enzyme, and rhCBSΔC represents unmodified rhCBSΔC enzyme. C57BL / 6J mice were injected with 5 mg / kg body weight of non-PEGylated rhCBSΔC (n=5) or GL4-400MA rhCBSΔC (n=5) at 0, 24, and 48 hours (arrows) and bled at the indicated time points. Plasma was analyzed for CBS activity using the radioactivity yield assay described in Example 1c. [Figure 3-1]FIG. 3 illustrates experimental evidence that a single injection of PEGylated rhCBSΔC reduces homocysteine and increases cystathionine in plasma. FIG. 3a is a graph showing that PEG modification of rhCBSΔC prolongs the systemic presence of CBS enzyme activity after a single SQ administration of rhCBSΔC modified with the indicated type of activated PEG. The graph shows the results of an experiment (n=3) in which 27 C57BL / 6J mice were divided into 9 experimental groups. Each experimental group was injected by the SQ route with 5 mg / kg body weight of rhCBSΔC PEGylated with the indicated PEG molecule or with non-PEGylated enzyme. ME020MA represents rhCBSΔC enzyme PEGylated with ME020MA, ME050GS represents rhCBSΔC enzyme PEGylated with ME050GS, ME200GS represents rhCBSΔC enzyme PEGylated with ME200GS, 200MA0B represents rhCBSΔC enzyme PEGylated with 200MA0B, ME400MA represents rhCBSΔC enzyme PEGylated with ME400MA, GL2400MA represents rhCBSΔC enzyme PEGylated with GL2400MA, GL4400MA represents rhCBSΔC enzyme PEGylated with GL4400MA, GL2800MA represents rhCBSΔC enzyme PEGylated with GL2800MA, and rhCBSΔC represents non-PEGylated rhCBSΔC enzyme. Blood samples were taken at the indicated time points and CBS enzyme activity was determined using a radioactive assay as described in Example 1c. Data are presented as histograms with standard deviations (STD) and as scatter plots. [Figure 3-2]Figure 3 illustrates experimental evidence that a single injection of PEGylated rhCBSΔC reduces homocysteine and increases cystathionine in plasma. Figure 3b is a bar graph showing the natural diurnal variation in Hcy, Cth, Cys, and Met levels in HO mouse plasma. The results are the average of six HO mice with blood taken at the indicated times throughout a 24-hour cycle (HO mouse model of homocystinuria as described in Maclean et al., 2010, Mol. Genet. Metab. 101: 153-62). Plasma amino acid levels were determined by Stable-Isotope-Dilution Liquid Chromatography-Mass Spectrometry for each time point as described in Example 1e. Figure 3c is a photograph of the results of electrophoretic analysis of rhCBSΔC PEGylated with ME-400MA (lane 1), GL4-400MA (lane 2) or ME-200MA0B (lane 3) separated by electrophoresis together with the non-PEGylated enzyme (lane 4) and stained with Coomassie blue (M indicates molecular weight standard). The specific activity (SA) for each of the PEGylated and non-PEGylated rhCBSΔC is shown in the table. [Figure 3-3] Figures 3d and 3e are bar graphs showing the results of an experiment in which HO mice were injected once at time 0 by SQ route with rhCBSΔC PEGylated with the indicated PEG molecules and bled at time 0 (pre-injection), 24 hours, 48 hours, and 72 hours after injection. Plasma homocysteine (d) and cystathionine (e) levels for each of the groups (n=5-6) are shown. With respect to Figures 3D and 3E, ME-200MA0B indicates rhCBSΔC enzyme PEGylated with ME-200MA0B, ME-400MA indicates rhCBSΔC enzyme PEGylated with ME-400MA, and GL4-400MA indicates rhCBSΔC enzyme PEGylated with GL4-400MA. [Figure 4-1]FIG. 4 illustrates experimental evidence that cessation of CBS treatment allows amino acid levels to return to pretreatment levels, while resumption of repeated injections of PEGylated rhCBSΔC significantly affects plasma levels of homocysteine and cystathionine, restoring normal cysteine levels. Six HO mice were injected with rhCBSΔC PEGylated with GL4-400MA PEG on days 0, 1, 2, 3 and 4, followed by a 10-day washout period, then reinjected on days 14, 15, 16, 17 and 18 (indicated by arrows). Plasma samples were taken (always before injection) on the following days: days 0, 2, 4, 5, 11, 14, 16, 18, 19, 24 and 31. For comparison, the same injection regimen was performed in five HO mice injected with non-PEGylated enzyme. Plasma metabolite levels were determined as described in Example 1e. For each individual HO mouse, FIG. 4a is a graph showing the results of homocysteine, and FIG. 4b is a graph showing the results of cystathionine plasma concentration. FIG. 4c is a graph showing the average concentration of homocysteine and cystathionine in plasma from HO mice treated throughout the study. FIG. 4d is a graph showing the effect of PEGylated rhCBSΔC on plasma homocysteine levels (shown as a percentage of time 0) compared to non-PEGylated rhCBSΔC throughout the study. GL4-400MA represents rhCBSΔC enzyme PEGylated with GL4-400MA, and rhCBSΔC represents unmodified rhCBSΔC enzyme. FIG. 4e is a graph showing the effect of PEGylated rhCBSΔC on plasma cysteine levels compared to non-PEGylated rhCBSΔC throughout the study. GL4-400MA represents rhCBSΔC enzyme PEGylated with GL4-400MA, and rhCBSΔC represents the unmodified rhCBSΔC enzyme. [Figure 4-2]FIG. 4 illustrates experimental evidence that cessation of CBS treatment allows amino acid levels to return to pretreatment levels, while resumption of repeated injections of PEGylated rhCBSΔC significantly affects plasma levels of homocysteine and cystathionine, restoring normal cysteine levels. Six HO mice were injected with rhCBSΔC PEGylated with GL4-400MA PEG on days 0, 1, 2, 3 and 4, followed by a 10-day washout period, then reinjected on days 14, 15, 16, 17 and 18 (indicated by arrows). Plasma samples were taken (always before injection) on the following days: days 0, 2, 4, 5, 11, 14, 16, 18, 19, 24 and 31. For comparison, the same injection regimen was performed in five HO mice injected with non-PEGylated enzyme. Plasma metabolite levels were determined as described in Example 1e. For each individual HO mouse, FIG. 4a is a graph showing the results of homocysteine, and FIG. 4b is a graph showing the results of cystathionine plasma concentration. FIG. 4c is a graph showing the average concentration of homocysteine and cystathionine in plasma from HO mice treated throughout the study. FIG. 4d is a graph showing the effect of PEGylated rhCBSΔC on plasma homocysteine levels (shown as a percentage of time 0) compared to non-PEGylated rhCBSΔC throughout the study. GL4-400MA represents rhCBSΔC enzyme PEGylated with GL4-400MA, and rhCBSΔC represents unmodified rhCBSΔC enzyme. FIG. 4e is a graph showing the effect of PEGylated rhCBSΔC on plasma cysteine levels compared to non-PEGylated rhCBSΔC throughout the study. GL4-400MA represents rhCBSΔC enzyme PEGylated with GL4-400MA, and rhCBSΔC represents the unmodified rhCBSΔC enzyme. [Figure 4-3]FIG. 4 illustrates experimental evidence that cessation of CBS treatment allows amino acid levels to return to pretreatment levels, while resumption of repeated injections of PEGylated rhCBSΔC significantly affects plasma levels of homocysteine and cystathionine, restoring normal cysteine levels. Six HO mice were injected with rhCBSΔC PEGylated with GL4-400MA PEG on days 0, 1, 2, 3 and 4, followed by a 10-day washout period, then reinjected on days 14, 15, 16, 17 and 18 (indicated by arrows). Plasma samples were taken (always before injection) on the following days: days 0, 2, 4, 5, 11, 14, 16, 18, 19, 24 and 31. For comparison, the same injection regimen was performed in five HO mice injected with non-PEGylated enzyme. Plasma metabolite levels were determined as described in Example 1e. For each individual HO mouse, FIG. 4a is a graph showing the results of homocysteine, and FIG. 4b is a graph showing the results of cystathionine plasma concentration. FIG. 4c is a graph showing the average concentration of homocysteine and cystathionine in plasma from HO mice treated throughout the study. FIG. 4d is a graph showing the effect of PEGylated rhCBSΔC on plasma homocysteine levels (shown as a percentage of time 0) compared to non-PEGylated rhCBSΔC throughout the study. GL4-400MA represents rhCBSΔC enzyme PEGylated with GL4-400MA, and rhCBSΔC represents unmodified rhCBSΔC enzyme. FIG. 4e is a graph showing the effect of PEGylated rhCBSΔC on plasma cysteine levels compared to non-PEGylated rhCBSΔC throughout the study. GL4-400MA represents rhCBSΔC enzyme PEGylated with GL4-400MA, and rhCBSΔC represents the unmodified rhCBSΔC enzyme. [Diagram 5]Figure 5 shows the variability in the degree of aggregation of human truncated CBS preparations (rhCBSΔC). Figure 5A is a Coomassie Blue stained 4-15% native gel of different batches of rhCBSΔC (112, 13, 7, 27 and 28). Note the different ratios between the tetrameric form of rhCBSΔC (T) and the dimeric form of rhCBSΔC (D) and also the higher forms of aggregated CBS. M indicates molecular weight marker. Figure 5B is an in-gel CBS activity assay of the native gel showing that the bands seen in Figure 5A for rhCBSΔC batches 112 and 28 are indeed CBS-related. Again, note the different ratios between the tetrameric form of rhCBSΔC (T) and the dimeric form of rhCBSΔC (D) and also the higher forms of aggregated CBS. FIG. 5C is an SDS PAGE gel (12%) showing PEGylation (+) with ME-200MA0B of two different rhCBSΔC batches showing various ratios (in the PEGylated (+) lane) between the two PEGylated species formed after PEGylation, while only the unmodified rhCBSΔC subunit is present when no PEG reagent is added (in the non-PEGylated (-) lane). [Figure 6A]FIG. 6 shows that human C15S mutant CBS only forms dimers. FIG. 6A is a native gel showing that C15S mutant CBS forms only dimers, in contrast to recombinant human truncated CBS (rhCBSΔC), which forms dimers (D) and tetramers (T), as well as higher oligomeric forms. TCEP (a reducing agent) does not affect the oligomeric state of the C15S mutant. M indicates molecular weight marker. FIG. 6B is a native gel showing various batches of C15S mutant CBS (51, 60, and 73), demonstrating that human C15S mutant CBS reproducibly forms only dimers, in contrast to rhCBSΔC without PEG (−) and after PEGylation with ME-200MA0B (+) and recombinant human doubly truncated (batch RC-2-76; a construct with an additional deletion of residues 2-39 of rhCBSΔC). PEGylation of either C15S or the doubly truncated constructs results in uniform and reproducible bands with similar ratios between PEGylated bands, in contrast to rhCBSΔC. Figure 6C is the same as Figure 6B, except that denaturing SDS PAGE was used. C15S results in a reproducible PEGylation pattern that differs from recombinant human truncated CBS (rhCBSΔC). This is also comparable to Figure 5C, which shows a non-reproducible PEGylation pattern with rhCBSΔC. [Figure 6B]FIG. 6 shows that human C15S mutant CBS only forms dimers. FIG. 6A is a native gel showing that C15S mutant CBS forms only dimers, in contrast to recombinant human truncated CBS (rhCBSΔC), which forms dimers (D) and tetramers (T), as well as higher oligomeric forms. TCEP (a reducing agent) does not affect the oligomeric state of the C15S mutant. M indicates molecular weight marker. FIG. 6B is a native gel showing various batches of C15S mutant CBS (51, 60, and 73), demonstrating that human C15S mutant CBS reproducibly forms only dimers, in contrast to rhCBSΔC without PEG (−) and after PEGylation with ME-200MA0B (+) and recombinant human doubly truncated (batch RC-2-76; a construct with an additional deletion of residues 2-39 of rhCBSΔC). PEGylation of either C15S or the doubly truncated constructs results in uniform and reproducible bands with similar ratios between PEGylated bands, in contrast to rhCBSΔC. Figure 6C is the same as Figure 6B, except that denaturing SDS PAGE was used. C15S results in a reproducible PEGylation pattern that differs from recombinant human truncated CBS (rhCBSΔC). This is also comparable to Figure 5C, which shows a non-reproducible PEGylation pattern with rhCBSΔC. [Figure 6C]FIG. 6 shows that human C15S mutant CBS only forms dimers. FIG. 6A is a native gel showing that C15S mutant CBS forms only dimers, in contrast to recombinant human truncated CBS (rhCBSΔC), which forms dimers (D) and tetramers (T), as well as higher oligomeric forms. TCEP (a reducing agent) does not affect the oligomeric state of the C15S mutant. M indicates molecular weight marker. FIG. 6B is a native gel showing various batches of C15S mutant CBS (51, 60, and 73), demonstrating that human C15S mutant CBS reproducibly forms only dimers, in contrast to rhCBSΔC without PEG (−) and after PEGylation with ME-200MA0B (+) and recombinant human doubly truncated (batch RC-2-76; a construct with an additional deletion of residues 2-39 of rhCBSΔC). PEGylation of either C15S or the doubly truncated constructs results in uniform and reproducible bands with similar ratios between PEGylated bands, in contrast to rhCBSΔC. Figure 6C is the same as Figure 6B, except that denaturing SDS PAGE was used. C15S results in a reproducible PEGylation pattern that differs from recombinant human truncated CBS (rhCBSΔC). This is also comparable to Figure 5C, which shows a non-reproducible PEGylation pattern with rhCBSΔC. [Figure 7A] Figure 7 shows size exclusion chromatography (SEC) analysis of rhCBSΔC (Figure 7A) and the C15S mutant (Figure 7B). Figure 7 provides further indication that the C15S mutant CBS exists only as a dimer, since it gives rise to one reproducible peak from five different purification batches (Figure 7B). Note the six different patterns of rhCBSΔC in Figure 7A and one peak of C15S CBS in Figure 7B. [Figure 7B]Figure 7 shows size exclusion chromatography (SEC) analysis of rhCBSΔC (Figure 7A) and the C15S mutant (Figure 7B). Figure 7 provides further indication that the C15S mutant CBS exists only as a dimer, since it gives rise to one reproducible peak from five different purification batches (Figure 7B). Note the six different patterns of rhCBSΔC in Figure 7A and one peak of C15S CBS in Figure 7B. [Figure 8] Figure 8 shows that continuous administration of the C15S mutant over a 20 day period in two HO mice results in a significant and sustained reduction in plasma homocysteine. The C15S mutant enzyme was administered using an ALZET® pump to continuously deliver the enzyme to the mice instead of repeated subcutaneous injections. ALZET® Pump, Model 1002 (average pump flow rate 0.21 μl / hr (for stock concentration 26.2 mg / mL), average fill volume 106.6 μl. The mice were bled at the indicated time points and Hcy was measured by mass spectrometry after isolation of plasma. [Figure 9] Figure 9 is a bar graph showing the results of an experiment in which HO mice were injected with a single dose (7.5 mg / kg) of rhCBSΔC, C15S mutant (C15S) and double truncated construct (double truncated) PEGylated with ME-200MA0B at time 0. The mice were bled at time 0 (pre-injection), 24 hours, 48 hours and 72 hours after injection. Plasma homocysteine levels for each of the groups (n=5-6) are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] (Detailed Description) Provided herein are forms of human cystathionine β-synthase (CBS), particularly suitable for pharmaceutical compositions and methods for treating individuals with homocystinuria, e.g., by enzyme replacement therapy (ERT).
[0023] The nucleic acid sequence encoding human CBS and the amino acid sequence encoded thereby are available through GenBank Accession No. L19501, and these sequences are also disclosed in U.S. Patent No. 5,523,225, which is incorporated by reference in its entirety. The coding sequence for CBS is represented herein as SEQ ID NO:1, which is the amino acid sequence of full-length human CBS, and the nucleic acid sequence encoding SEQ ID NO:2, which has 551 amino acid residues. The nucleic acid sequence of genomic DNA encoding CBS is also publicly available through sequence databases (e.g., GenBank) and at the University of Colorado-Denver web page under the Kraus Lab.
[0024] As used herein, isolated truncated versions of cystathionine beta-synthase proteins (CBS proteins), particularly human CBS proteins, may include, but are not limited to, purified truncated CBS proteins, chemically truncated and recombinantly produced truncated CBS proteins, and isolated CBS proteins associated with other proteins. More specifically, an isolated protein, according to the present invention, is a protein (including a polypeptide or peptide) that has been isolated from its natural environment (i.e., subjected to human manipulation) and may include, for example, purified proteins, partially purified proteins, recombinantly produced proteins, and synthetically produced proteins. Thus, "isolated" does not reflect the degree to which a protein has been purified. The isolated truncated CBS proteins of the present invention may be recombinantly produced in a cell (e.g., a bacterial cell). Additionally, and by way of example, "human truncated CBS proteins" refers to truncated CBS proteins (as shown herein) derived from humans (Homo sapiens) or CBS proteins otherwise produced from knowledge of the structure (e.g., sequence) and possibly function of naturally occurring CBS proteins derived from Homo sapiens. In other words, human truncated CBS proteins include biologically active truncated human CBS proteins, as described in detail herein.
[0025] As used herein, the term "variant" or "mutant" is used to refer to a protein or peptide that differs from a naturally occurring protein or peptide (i.e., a "prototype" or "wild-type" protein) by modifications to the naturally occurring protein or peptide, but maintains the basic protein and side chain structure of the naturally occurring form. Such modifications include, but are not limited to, modifications in one, a few, or even a few amino acid side chains; modifications in one, a few, or even a few amino acids (e.g., a cysteine at position 15 to a serine; C15S); modifications in the stereochemistry of one or a few atoms; and / or minor derivatizations, including, but not limited to, methylation, glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitoylation, amidation, and / or addition of glycosylphosphatidylinositol. A "variant" or "mutant" may have enhanced, decreased, altered, or essentially similar properties compared to the naturally occurring protein or peptide. In certain embodiments, the invention provides truncated CBS proteins having C-terminal deletions of the naturally occurring CBS proteins described above.
[0026] As used herein, the term "homolog" or "ortholog" refers to a protein sequence or DNA sequence that shares a common ancestor and may be essentially the same protein or DNA sequence in different species. Homolog and ortholog proteins and genes often have similar amino acid and nucleotide sequences, or high sequence similarity, respectively (e.g., homologous proteins may have 50%, 60%, 70%, 80%, 90%, 95% or more amino acid sequence similarity).
[0027] Methods for measuring protein expression levels of CBS according to the present invention include, but are not limited to: Coomassie blue or silver staining of proteins in separation media (e.g., gel electrophoresis), Western blotting, immunocytochemistry, other immunological-based assays; assays based on protein properties (including, but not limited to, enzyme assays, ligand binding, or interactions with other protein partners). Binding assays are also well known in the art. For example, BIAcore instruments can be used to determine the binding constant of a complex between two proteins. The dissociation constant of the complex can be determined by monitoring the change in refractive index versus time as a buffer passes over the chip. Other suitable assays for measuring the binding of one protein to another include, for example, immunoassays such as enzyme-linked immunosorbent assays (ELISAs) and radioimmunoassays (RIAs), or binding determinations by monitoring changes in the spectroscopic or optical properties of the proteins through fluorescence, UV absorption, circular dichroism, or nuclear magnetic resonance (NMR).
[0028] In certain aspects, the CBS variants may include any combination of N-terminal deletions or modifications (e.g., deletion of N-terminal residues 2-39 or 1-70) and C-terminal deletions or modifications (e.g., deletion of C-terminal residues 383-551, 397-551, 414-551, 442-551, 489-551, 497-551, 524-551, 534-551, or 544-551) described herein or in U.S. Pat. Nos. 7,485,307 and 8,007,787, both of which are incorporated herein by reference. In another embodiment, further modifications may be achieved by modification of other amino acid residues to provide a given % identity to the wild-type CBS sequence. In a particular embodiment, the human CBS variant of the invention in which the C-terminal regulatory region has been removed is a truncated recombinant human CBS (rhCBSΔC) homodimeric enzyme (SEQ ID NO:3). In another embodiment, a human CBS variant of the invention is rhCBSΔC (SEQ ID NO: 13), in which the cysteine at amino acid position 15 has been mutated to serine (C15S).
[0029] In other embodiments of the invention, any of the CBS variants described herein have no more than one or two non-CBS amino acid residues at the N-terminus (i.e., the variant contains no more than one or two amino acid residues at the N-terminus that are not residues of the naturally occurring human cystathionine β-synthase amino acid sequence). Such variants can be produced, for example, using the novel methods for recombinant CBS production described below.
[0030] In further embodiments, any of the above CBS variants of the invention (including any truncated CBS proteins) comprise an amino acid sequence that is at least about 50% identical, or at least about 55% identical, or at least about 60% identical, or at least about 65% identical, or at least about 70% identical, or at least about 75% identical, or at least about 80% identical, or at least about 85% identical, or at least about 90% identical, or at least about 95% identical, or at least about 96% identical, or at least about 97% identical, or at least about 98% identical, or at least about 99% identical to the wild-type amino acid sequence set forth by SEQ ID NO:2, or a biologically active truncation thereof; particularly comprising a non-heme binding or non-S-adenosylmethionine (AdoMet) binding, wherein the variant remains catalytically active (e.g., wherein certain truncated forms of CBS may be more active in the presence of AdoMet than full-length CBS). In a particular embodiment, the human CBS variant of the invention is a truncated recombinant human CBS (rhCBSΔC) homodimeric enzyme in which its C-terminal regulatory region has been removed (SEQ ID NO: 3). In another embodiment, the human CBS variant of the invention is a truncated recombinant human CBS enzyme in which the cysteine at amino acid position 15 has been mutated to serine (SEQ ID NO: 13).
[0031] In certain embodiments, the CBS proteins of the present invention include amino acid sequences that are less than 100% identical to SEQ ID NO:2, particularly truncated embodiments thereof having the amino acid sequences of truncated variants as set forth in U.S. Pat. No. 8,007,787, and in particular SEQ ID NO:3 and SEQ ID NO:13 as set forth herein, and in specific embodiments, truncated variants as set forth in U.S. Pat. No. 8,007,787, and in particular SEQ ID NO:3 and SEQ ID NO:13 as set forth herein, including amino acid sequences having less than 99% sequence identity, less than 98% sequence identity, less than 97% sequence identity, less than 96% sequence identity, less than 95% sequence identity, less than 94% sequence identity, less than 93% sequence identity, less than 92% sequence identity, less than 91% sequence identity, less than 90% sequence identity, etc.
[0032] As used herein, unless otherwise specified, references to percent (%) identity refer to assessment of homology using sequence alignment tools or programs, including, but not limited to: (1) BLAST 2.0 Basic BLAST homology search, using standard default parameters, such as blastp for amino acid searches and blastn for nucleic acid searches, where the query sequence is filtered for low complexity regions by default; (2) BLAST 2 alignment, using parameters described below; (3) and / or PSI-BLAST (Position-Specific Iterated BLAST), using standard default parameters. Due to some differences in standard parameters between BLAST 2.0 Basic BLAST and BLAST 2, two particular sequences may be recognized as having significant homology using the BLAST 2 program, whereas BLAST using one of the sequences as the query sequence may be used. It is noted that searches performed in 2.0 Basic BLAST may not identify the second sequence in the top match. In addition, PSI-BLAST provides an automated, easy-to-use version of the "profile" search, which is a sensitive method for finding sequence homologs. The program first performs a gapped BLAST database search. The PSI-BLAST program uses information from any significant alignments returned to construct a position-specific score matrix, which replaces the query sequence for the next round of database searching. Thus, it should be understood that percent identity can be determined by using any of these programs.
[0033] CBS derivatives are included within the scope of the present invention. Such derivatives are chemically modified CBS polypeptide compositions in which a CBS polypeptide is linked to a polymer. The polymer selected is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous environment and the CBS enzyme is biologically active in biological fluids (e.g., physiological environments). The polymer may be of any molecular weight and may be branched or unbranched. Included within the scope of CBS polypeptide polymers are mixtures of polymers. In a specific embodiment, for therapeutic use in the final product preparation, the polymer is pharma- ceutical acceptable.
[0034] The water-soluble polymer or mixtures thereof may be selected from the group consisting of, for example, polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran (e.g., low molecular weight dextran (e.g., about 6 kDa)), cellulose, or other carbohydrate-based polymers, poly-(N-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polysalicylic acid, and polyvinyl alcohol. Bifunctional PEG cross-linking molecules that may be used to prepare covalently linked CBS polypeptide multimers are also encompassed by the invention. In one embodiment, the polyethylene glycol molecule is selected from unbranched and branched polyethylene glycol, wherein the polyethylene glycol molecule has a molecular weight of 2000 Daltons or greater. In another embodiment, the polyethylene glycol molecule may have a molecular weight in the range of 2-100 kD, 5-80 kD, or 10-40 kD. In yet another embodiment, the polyethylene glycol molecule is selected from ME-200MA0B, ME-020MA, ME-400MA, GL2-400MA, GL4-400MA, GL2-800MA, ME-050GS, ME-200GS, ME-200AL, or MEPA-20T.
[0035] In certain embodiments, the invention provides a truncated recombinant human CBS (rhCBSΔC) homodimeric enzyme, in which the C-terminal regulatory region has been removed (SEQ ID NO:3) and has been chemically modified by covalent attachment with polyethylene glycol (PEG), including the "PEGylated species" referred to herein. In other embodiments of the invention, the human CBS variant of the invention is a truncated recombinant human CBS enzyme, in which the cysteine at amino acid position 15 has been mutated to a serine (SEQ ID NO:13) and has been chemically modified by covalent attachment with polyethylene glycol (PEG), including the "PEGylated species" referred to herein.
[0036] Specific embodiments of the various PEG reagents used in the PEGylation reactions to generate the modified PEGylated species are identified in Table 1.
[0037] [Table 1] PEGylation of CBS polypeptides can be carried out by any of the PEGylation reactions known in the art. PEGylation can be carried out by acylation or alkylation reactions with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer), as described below. For acylation reactions, the selected polymer should have a single reactive ester group. For reductive alkylation, the selected polymer should have a single reactive aldehyde group. The reactive aldehyde can be, for example, polyethylene glycol propionaldehyde, which is stable in water, or its mono C1-C 10In one embodiment, the polyethylene glycol molecule is linked to the CBS by a linking group selected from N-hydroxysuccinimide (NHS), amines, and aldehydes of monoaldehydes, monoesters of monoacids, monoamines, monothiols, monodisulfides, monobromophenyl carbonates, monochlorophenyl carbonates, monofluorophenyl carbonates, mononitrophenyl carbonates, monocarbonylimidazoles, monohydrazides, monoiodoacetamides, monomaleimides, monoorthopyridyl disulfides, monooximes, monophenylglyoxals, monothiazolidine-2-thiones, monothioesters, monotriazines, and monovinyl sulfones.
[0038] One water-soluble polymer for use herein is polyethylene glycol (abbreviated as PEG). As used herein, polyethylene glycol refers to any of the forms of PEG that have been used to derivatize other proteins, such as mono-(C1-C2H4, C1-C3H4, C1-C2H5, C1-C3H6, C1-C2H7, C1-C3H8, C1-C3H9, C1-C4H10, C1-C4H11, C1-C4H12, C1-C4H13, C1-C4H14, C1-C4H15, C1-C4H20, C1-C4H16, C1-C4H20, C1-C4H17, C1-C4H20, C1-C4H18, C1-C4H19, C1-C5H20, C1-C6H11, C1-C7H12, C1- 10 ) alkoxy- or aryloxy-polyethylene glycols).
[0039] In general, chemical derivatization can be performed under any suitable conditions used to react biologically active substances with activated polymer molecules. Methods for preparing PEGylated CBS polypeptides generally include (a) reacting the polypeptide with polyethylene glycol (e.g., a reactive ester, amine, aldehyde, or maleimide derivative of PEG) under conditions in which the CBS polypeptide is conjugated with one or more PEG groups, and (b) obtaining the reaction product. In general, optimal reaction conditions for the acylation reaction are determined based on known parameters and desired results. For example, the higher the PEG:protein ratio, the greater the percentage of poly-PEGylated product. In one particular aspect, the CBS polypeptide derivative has a single PEG moiety at the amino terminus. In certain embodiments, the PEGylated CBS enzymes provided by the present invention have an average of about 1 to about 10, more particularly, 2 to about 5, and more particularly, 3 to 5 PEG molecules covalently attached to each enzyme subunit in the composition.
[0040] The proteins of the present invention are preferably recovered, obtained, and / or used in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of said proteins in vitro, ex vivo, or in vivo according to the present invention. With respect to a protein useful in an in vitro, ex vivo, or in vivo method according to the present invention, it is substantially free of contaminants, other proteins, and / or chemicals that may or would interfere with its use in the methods disclosed by the present invention, or that are at least undesirable for inclusion with the CBS protein (including homologs) when it is used in the methods disclosed by the present invention. Such methods include enzymatic reactions (e.g., the production of cystathionine), preparation of therapeutic compositions, administration in therapeutic compositions, and all other methods disclosed herein. A "substantially pure" protein, as referred to herein, may be produced by any method (i.e., by direct purification from a natural source, recombinantly, or synthetically) and is a protein that has been purified from other protein components such that the protein constitutes at least about 80% by weight of the total protein in a given composition (e.g., the CBS protein is about 80% of the protein in a solution / composition / buffer), and more preferably constitutes at least about 85%, and more preferably at least about 90%, and more preferably at least about 91%, and more preferably at least about 92%, and more preferably at least about 93%, and more preferably at least about 94%, and more preferably at least about 95%, and more preferably at least about 96%, and more preferably at least about 97%, and more preferably at least about 98%, and more preferably at least about 99% by weight of the total protein in a given composition. In embodiments of the above CBS proteins or truncated variants thereof produced in recombinant bacteria, the terms "purified" or "substantially pure" are understood to include purification from lipopolysaccharides and other pyrogenic compounds.
[0041] It will be appreciated by those skilled in the art that the use of recombinant DNA technology can improve the control of expression of transfected nucleic acid molecules, for example, by manipulating the copy number of the nucleic acid molecules in the host cell, the efficiency with which they are transcribed, the efficiency with which the resulting transcripts are translated, and the efficiency of post-translational modifications. Furthermore, promoter sequences can be genetically engineered to improve expression levels compared to the native promoter.
[0042] Recombinant techniques useful for controlling expression of a nucleic acid molecule include, but are not limited to, integration of the nucleic acid molecule into one or more host cell chromosomes, addition of vector stabilizing sequences to a plasmid, replacement or modification of transcriptional control signals (e.g., promoters, operators, enhancers), replacement or modification of translational control signals (e.g., ribosome binding sites, Shine-Dalgarno sequences), modification of the nucleic acid molecule to correspond to the codon usage of the host cell, and deletion of sequences that destabilize the transcript.
[0043] In a further aspect, the present invention relates to a method for recombinantly producing and purifying human cystathionine-β-synthase, comprising cloning a nucleic acid sequence encoding the human CBS enzyme or a truncated or mutated variant as set forth in US Patent No. 8,007,787 and specifically SEQ ID NO: 4 herein into an expression vector. In certain embodiments, the human CBS coding sequence is modified to utilize codons optimized for expression in a microorganism (e.g., E. coli). In other embodiments, the vector comprises: (a) a cloning site for linking a fusion partner (e.g., glutathione S-transferase, or GST) to the nucleic acid sequence to be expressed, and (b) a protease cleavage recognition site for a protease using human rhinovirus 3C protease (e.g., available from GE Healthcare as a fusion protein called PreScission protease) or a similar cleavage site, to cleave the fusion partner from the CBS protein after expression of the recombinant fusion protein. As part of the present invention, the expression vector is first genetically modified for the specific introduction of a CBS-encoding nucleic acid sequence that results in the expression of a CBS fusion protein that can be cleaved by human rhinovirus 3C protease, such that a CBS protein with only one additional non-CBS, N-terminal amino acid residue is generated. This outcome is not possible using the unmodified multiple cloning site in commercially available vectors. The CBS-encoding nucleic acid sequence is introduced into the genetically modified vector, the recombinant fusion protein is expressed and purified using conventional methods or those suitable for CBS production (see, e.g., U.S. Pat. No. 5,635,375, supra), and finally, the fusion partner and all but one of the non-CBS amino acid residues are cleaved from the CBS protein, leaving a highly purified, almost entirely human recombinant CBS protein that is ideal for use in human therapeutic applications. In a particularly advantageous embodiment, the nucleotides encoding the human CBS protein are engineered to the codon usage of the recombinant cell in which it is recombinantly produced.A non-limiting example of such an embodiment is shown herein as SEQ ID NO:4, in which a CBS-encoding nucleic acid has been adapted for optimal recombinant expression in E. coli.
[0044] Some aspects of the invention include compositions comprising any of the CBS variants described herein for in vitro generation of cystathionine or cysteine, for in vitro removal or generation of hydrogen sulfide, or for in vivo therapeutic use (e.g., for treating or preventing homocystinuria and related conditions). Accordingly, another embodiment of the invention relates to compositions comprising isolated CBS proteins and in particular truncated variants thereof, as set forth in U.S. Pat. No. 8,007,787, and specifically as set forth in SEQ ID NO:3 or SEQ ID NO:13 as described herein. The compositions typically also include a pharma- ceutically acceptable carrier. The compositions and their components may be used in any of the in vitro or therapeutic embodiments of the invention described herein.
[0045] As used herein, the "HO" mouse is a new mouse model of classical homocystinuria in which the mouse cbs gene is inactivated and the mouse exhibits low-level expression of a human CBS transgene under the control of the human CBS promoter. This mouse model exhibits severe elevations in both plasma and tissue levels of Hcy, methionine, S-adenosylmethionine, and S-adenosylhomocysteine, and a concomitant decrease in plasma and liver levels of cysteine. See Maclean et al., 2010 Mol. Genet. Metab. 101:153-62).
[0046] The compositions of the invention are useful for generating cystathionine and cysteine in vitro or for treating individuals who would benefit from increased CBS activity (eg, individuals with homocystinuria).
[0047] According to the present invention, a "pharmaceutical acceptable carrier" includes a pharmaceutical acceptable excipient and / or a pharmaceutical acceptable delivery vehicle, which are suitable for use in administering the composition to a suitable in vitro, ex vivo or in vivo site. The suitable in vitro, in vivo or ex vivo site is preferably any site where it is desired to modulate CBS activity. A pharmaceutical acceptable carrier can maintain the protein or recombinant nucleic acid molecule of the present invention in a form in which the protein or recombinant nucleic acid molecule can interact with its target (e.g., a substrate of CBS) when the protein or recombinant nucleic acid molecule reaches a target cell or tissue in a culture or an individual.
[0048] Suitable excipients of the present invention include excipients or formulations that transport or aid in transport but do not specifically target the composition to cells (also referred to herein as non-targeting carriers). Examples of pharmaceutically acceptable excipients include, but are not limited to: water, phosphate-buffered saline, Ringer's solution, dextrose solution, serum-containing solution, Hank's solution, other aqueous physiological buffers, oils, esters and glycols. Aqueous carriers may contain suitable auxiliary substances necessary to approximate the physiological conditions of recipients, for example, by enhancing chemical stability and isotonicity. The compositions of the present invention may be sterilized and / or lyophilized by conventional methods.
[0049] One type of pharma-ceutically acceptable carrier includes sustained release formulations that can slowly release the composition of the present invention into an individual or culture. As used herein, sustained release formulations include the compound of the present invention (e.g., protein (including homologues), antibody, nucleic acid molecule, or mimetic) in a sustained release vehicle. Suitable sustained release vehicles include, but are not limited to: biocompatible polymers, other polymer matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps (e.g., ALZET® osmotic pumps), diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other carriers of the present invention include liquids that form solids or gels in situ when administered to an individual. In a specific embodiment, the carrier is also biodegradable (i.e., biodegradable). When the compound is a recombinant nucleic acid molecule, suitable carriers include, but are not limited to: liposomes, viral vectors, or other carriers (including ribozymes, gold particles, poly-L-lysine / DNA-molecule conjugates, and artificial chromosomes). Natural lipid-containing carriers include cells and cell membranes. Artificial lipid-containing carriers include liposomes and micelles.
[0050] The carrier of the present invention may be modified to target a particular site in an individual, thereby targeting and utilizing the protein of the present invention at that site. A pharma- ceutically acceptable carrier capable of targeting may also be referred to herein as a "delivery vehicle" or "targeting carrier." Suitable modifications include manipulating the chemical formula of the lipid portion of the delivery vehicle and / or introducing a targeting agent into the vehicle that can specifically target the delivery vehicle to a preferred or target site (e.g., a preferred cell type). A "targeting site" refers to a site in an individual to which delivery of a composition is desired. Alternatively, the pharma- ceutically acceptable carrier may include an agent suitable for delivering the CBS protein to an animal (preferably a human), into the plasma or serum. Suitable targeting compounds include ligands that can selectively (i.e., specifically) bind another molecule at a particular site. Examples of such ligands include antibodies, antigens, receptors, and receptor ligands. Manipulation of the chemical formula of the lipid portion of the delivery vehicle may regulate the extracellular or intracellular targeting of the delivery vehicle. For example, chemicals can be added to the lipid formula of liposomes that change the charge of the lipid bilayer of the liposomes so that the liposomes will fuse with specific cells having specific charge characteristics. In specific embodiments, the liposomes of the present invention include, for example, those liposomes commonly used in protein delivery methods known to those of skill in the art. Complexation of the liposomes with the proteins of the present invention can be achieved using methods standard in the art.
[0051] In yet another aspect, the present invention relates to methods for regulating biological processes, including cystathionine production, by regulating expression and / or activity of CBS. This embodiment may include the use (e.g., administration) of therapeutic compositions comprising one or more of the CBS variants, particularly truncated CBS variants thereof, as set forth in U.S. Pat. No. 8,007,787, and specifically as set forth herein in SEQ ID NO:3 or SEQ ID NO:13, useful in methods for regulating the production of cystathionine mediated by or associated with CBS expression and biological activity.
[0052] Thus, in one embodiment, the method of the invention modulates cystathionine production in an animal or human individual, wherein the individual is protected from or treated for a disease susceptible to modulation of cystathionine production, such as homocystinuria and related conditions / symptoms thereof (e.g., ectopia lentis, skeletal disorders, mental retardation, and premature arteriosclerosis and thrombosis). As used herein, the phrase "protected from a disease" refers to reducing the symptoms of the disease; reducing the occurrence of the disease, and / or reducing the severity of the disease. Protection of an individual refers to the prevention or treatment of a disease symptom, sign, or progression from a disease, when the therapeutic composition of the invention, when administered to the individual, is administered to the individual. It may refer to the ability to prevent the disease from occurring and / or cure or treat the disease by alleviating the cause. Thus, protecting an individual from disease includes both preventing disease occurrence (prophylactic treatment) and treating an individual who has disease or experiences early or late stage symptoms of disease (therapeutic treatment). The term "disease" refers to any deviation from an individual's normal health state, including the state where disease symptoms are present, and the state where deviations (e.g., in non-limiting examples, infection, genetic mutation, genetic defect, etc.) have occurred but symptoms have not yet appeared (e.g., pre-disease state).
[0053] More specifically, a therapeutic composition as described herein, when administered to an individual by the methods of the invention, preferably produces a result that may include alleviation of the disease (e.g., reduction of at least one symptom or clinical manifestation of the disease), elimination of the disease, alleviation of a secondary disease resulting from the occurrence of a primary disease, or prevention of the disease. In a further aspect, administration of the therapeutic composition may produce a result that may include increased accumulation of a downstream metabolite of sulfur-containing substituent transfer in a mammal.
[0054] According to the present invention, an effective administration protocol (i.e., administering a therapeutic composition in an effective manner) preferably includes appropriate dose parameters and modes of administration that produce a desired effect in the individual (e.g., increasing the activity of cystathionine-β-synthase in the individual, or increasing the condensation of serine and homocysteine to form cystathionine) so that the individual is protected from the disease (e.g., by disease prevention or by alleviating one or more symptoms of an ongoing disease). Effective dose parameters can be determined using methods standard in the art for a particular disease. Such methods include, for example, determining survival rates, side effects (i.e., toxicity), and disease progression or regression.
[0055] According to the present invention, a suitable single dose size is a dose that, when administered one or more times over a suitable period of time, results in an increase in CBS activity or control of Hcy levels for an individual at the individual's normal protein intake or formation of cystathionine or cysteine, or an improvement in at least one symptom of the condition in the individual.Dosages may vary depending on the disease being treated.Those skilled in the art can easily determine the suitable single dose size for a given individual based on the size of the individual and the route of administration.
[0056] In certain embodiments of the present invention, a suitable single dose of the therapeutic composition of the present invention is an amount that, when administered by any route of administration, increases CBS activity as described above, compared to an individual who has not been administered the therapeutic composition of the present invention (i.e., a predetermined control individual or measurement), compared to an individual prior to administration of the composition, or compared to a standard established for the particular disease, individual type, and composition. The administered therapeutic composition is enzymatically active for an extended period of time. This period is preferably greater than 24 hours. The chemically modified therapeutic composition retains 70% or more of the initial activity of the administered composition after 24 hours. More preferably, the period of effective enzymatic activity of the administered therapeutic composition is greater than 48 hours. Even more preferably, the period of effective enzymatic activity of the administered therapeutic composition is greater than 72 hours. In certain embodiments, the therapeutic composition can be administered several times (e.g., 2 or 3 times or more) per day, or less frequently (including, but not limited to, once a week, once every two weeks, once a month, once every two months, or less frequently). In other embodiments, the therapeutic composition may be administered continuously over the course of days, weeks or months. In another embodiment of the invention, an appropriate dose of a therapeutic composition of the invention may be administered in conjunction with betaine (e.g., CYSTADANE®), a fairly relaxed protein restricted diet, anticoagulants, or statins.
[0057] As discussed above, the therapeutic compositions of the present invention are administered to an individual in a manner effective to deliver the composition to cells, tissues, and / or the whole body of the individual, whereby a desired result is achieved as a result of administration of the composition. Suitable administration protocols include any in vivo or ex vivo administration protocols. Preferred administration routes will be clear to those skilled in the art depending on the type of condition to be prevented or treated; whether the composition is nucleic acid-based, protein-based, or cell-based; and / or the target cell / tissue. For proteins, methods of in vivo administration include parenteral administration, specifically including, but not limited to, osmotic pump administration, intravenous administration, intraperitoneal administration, intramuscular administration, intranodal administration, intracoronary administration, intraarterial administration (e.g., into the carotid artery), subcutaneous administration, intraarticular administration, intraventricular administration, and direct injection into tissue. A combination of delivery routes may be used, which in some instances may enhance the therapeutic effect of the composition.
[0058] Many of the above routes of administration, including intravenous, intraperitoneal, intradermal, intramuscular or via osmotic pump, can be performed using methods standard in the art.
[0059] One method of local administration is by direct injection.Direct injection technique is particularly useful for administering compositions to cells or tissues that are accessible by surgery, and especially to or near the surface of the body.Administering compositions locally in the area of target cells refers to injecting the composition centimeters and preferably millimeters away from the target cells or tissues.
[0060] Another method of local administration is by the use of one or more osmotic pumps (e.g., ALZET® osmotic pumps). The pumps allow for constant delivery of drugs over extended periods of time (e.g., weeks or months). Implantable osmotic pumps are particularly useful for administering compositions to cells, tissues or subjects that are accessible by surgery, and especially to or near the surface of the body. Administering a composition locally within the region of a target cell or tissue of a subject refers to implanting an osmotic pump containing the composition several centimeters and preferably several millimeters from the target cell or tissue.
[0061] In the method of the present invention, the therapeutic composition can be administered to any member of the vertebrate class, mammals, including but not limited to primates, rodents, livestock and domestic pets. Livestock includes animals that are consumed or produce useful products, such as sheep for wool. Preferred individuals to protect include humans.
[0062] Some aspects of the invention include the use of any of the CBS variants described herein to generate isolated CBS polypeptides or non-aggregated CBS derivatives.
[0063] Each reference described and / or cited herein is incorporated by reference in its entirety. The following examples are provided for illustrative purposes and are not intended to limit the scope of the present invention. EXAMPLES
[0064] Example 1: Production of truncated CBS proteins in bacteria a. Recombinant expression of truncated CBS proteins in bacteria A truncated human CBS variant lacking specific portions of the non-conserved region (rhCBSΔC; SEQ ID NO:3) was constructed and expressed in an E. coli -based expression system as previously described (Kozich and The CBS protein was overexpressed using the pKK388.1 (Kraus, 1992, supra). A construct encoding the truncated human CBS protein variant rhCBSΔC (DNA encoding rhCBSΔC is shown in SEQ ID NO:4) was generated by modification of a previously described pHCS3 CBS expression construct (Kozich and Kraus, 1992, Hum. Mutat. 1:113-123) containing the full-length CBS coding sequence (SEQ ID NO:1) cloned into pKK388.1. To generate C-terminal deletion constructs, CBS cDNA fragments spanning the desired nucleotide residues were amplified using primers that incorporated Sph I and Kpn I sites at the 5' and 3' ends of the PCR products, respectively. All PCR products were then cut with Sph I and Kpn I and cloned by ligation into the Sph I and Kpn I digested pHCS3 vector. An Sph I site naturally occurs in the CBS cDNA above, immediately upstream of the antisense primer hybridization site (base pair position 1012, according to the CBS cDNA numbered as SEQ ID NO: 1). The PCR product so generated was then digested with Nco I and Sph I and ligated into the pHCS3 plasmid cut with the same enzymes.
[0065] [ka] Finally, the construct was transformed into E. coli BL21 (Stratagene). The authenticity of the construct was verified by DNA sequencing using a Thermo Sequenase Cy5.5 sequencing kit (Amersham Pharmacia Biotech) and a Visible Genetics Long-Read Tower System-V3.1 DNA sequencer according to the manufacturer's instructions.
[0066] For bacterial expression analysis of CBS deletion mutants, growth of E. coli BL21 cells harboring CBS truncation mutant constructs, induction of expression, and production of crude cell lysates were performed as previously described (Maclean et al., 2002, Hum. Mutat. 19:641-55).
[0067] An alternative method was also used to generate a sequence-optimized truncated human CBS enzyme (rhCBSΔC; SEQ ID NO: 3) in the pET28a(+) vector. The full-length (551 aa) human CBS coding sequence was optimized for bacterial expression and cloned into the pUC57 vector after digestion with EcoRV restriction enzyme by GenScript USA Inc. (NJ, USA). The CBS sequence was then amplified by PCR using primers A1 and A2 to generate the sequence encoding the truncated enzyme (aa 1-413):
[0068] [ka] The PCR product was then digested with restriction enzymes NcoI and XhoI and ligated into the pET-28a(+) vector (commercially available from EMD Millipore, Billerica, MA) digested with the same enzymes. Cloning into the optimal NcoI site of pET-28a(+) results in a G→C mutation compared to the CBS wild-type sequence (encoding alanine instead of proline). Therefore, a site-directed mutagenesis kit (Stratagene, CA, USA) utilizing primers B1 and B2 was used to regenerate the wild-type sequence encoding proline:
[0069] [ka] The same strategy was used to generate the C15S mutant (T→A mutation) using the following primers:
[0070] [ka] The entire sequences of both the optimized rhCBSΔC and C15S mutant polynucleotide constructs were verified by sequencing.
[0071] Expression of the truncated CBS is controlled by an upstream T7 promoter in the pET-28a(+) vector and requires transformation into DE3 bacteria and induction with IPTG.
[0072] (b. Expression of sequence-optimized truncated human CBS enzyme) The pET-28a(+) vector carrying the sequence encoding the truncated human CBS was transformed into DE3 bacteria, i.e., HMS174(DE3) or BL-21(DE3), and kanamycin resistant clones were selected and maintained as stock glycerol at -80°C for further use.
[0073] Bacteria from the stock glycerol were grown overnight in 5 ml of Luria-Bertani (LB) medium containing 30 μg / ml kanamycin at 37° C. on a rotary shaker at 275 RPM. The following morning, 1 ml of the overnight culture was added to 100 ml Terrific Broth (TB) medium containing 30 μg / ml kanamycin and grown overnight as above. 10 ml of the overnight culture was then added to 1 liter of TB medium containing the following supplements: 0.001% Thiamine-HCl (pH 8.0) 0.0025% Pyridoxine-HCl (pH 8.0) 0.3mM δ-(aminolevulinic acid) (δ-ALA) pH 8.0 150μM ferric chloride Kanamycin at 30 μg / ml.
[0074] The 1 liter culture was then cultured at OD 600The cells were grown on a rotary shaker at 275 RPM at 30°C until the β-actin reached a value of approximately 0.6-0.7, and protein expression was induced by adding 1 mM IPTG. Fermentation was continued for an additional 16 hours. Cells were then harvested by 6000 RCF centrifugation at 4°C for 10 minutes, washed with ice-cold 0.9% NaCl, centrifuged again as above, and frozen at -80°C.
[0075] An aliquot (4.45 ml of lysis buffer (20 mM NaH2PO4, pH=7.2, 40 mM NaCl, 0.1 mM PLP) per gram of pellet) was then added to the cell pellet and the latter was homogenized in a Dounce homogenizer until no cell aggregates were visible. The homogenate was then treated with lysozyme (2 mg / ml final), incubated for 1 h at 4° C. on a shaking platform, sonicated to reduce viscosity, and centrifuged at 53,000 RCF. The supernatant containing the soluble fraction was then stored at −80° C.
[0076] Expression levels were verified by gel electrophoresis followed by Coomassie gel staining, and specific activity was determined by radioactivity assay.
[0077] (c.CBS Assay) CBS activity was measured using the labeled substrate [ 14 The concentration of CBS was determined by a previously described radioisotopic assay using [C] serine (Kraus, 1987, Methods Enzymol. 143,388-394). Protein concentration was determined by the Bradford method (Bradford, 1976, Anal. Biochem. 72, 248-254) using bovine serum albumin (BSA) as the standard. One unit of activity is defined as the amount of CBS that catalyzes the formation of 1 μmol of cystathionine at 37° C. for 1 h.
[0078] (d. Denaturing and native polyacrylamide gel electrophoresis and Western blotting) Western blot analysis of CBS samples under both denaturing and native conditions was performed as previously described (Majtan et al., 2010 J Biol Chem. 2010;285(21):15866-73).
[0079] (e. Determination of Plasma Metabolites) Using the Stable-Isotope-Dilution Liquid Chromatography-Mass Spectrometry method, Allen et al. 93, Serum betaine N, N-dimethylglycine and N-methylglycine levels in individuals with cobalamin and folate deficiency and related inborn errors of metabolism, Metabolism 42: 1448-1460, The levels of sulfur amino acid metabolism compounds in plasma were measured.
[0080] Example 2: In vivo plasma retention time is enhanced following rhCBSΔC PEGylation Experiments were performed to evaluate the retention time and activity of rhCBSΔC in the blood circulation, in which C57BL / 6J mice were injected with 5 mg / kg body weight of rhCBSΔC by intraperitoneal (IP), intravascular (IV) or subcutaneous (SQ) routes. To avoid excessive blood sampling, two experimental groups (designated 1 and 2) of 5 mice each were used for each injection route (total n=30). For each injection route, blood was collected from group 1 at 0, 1, 8 and 24 hours after injection, and from group 2 at 1, 4, 10 and 48 hours after injection. Animals were bled with a single-use lancet for submandibular blood sampling, and blood was collected in Capiject T-MLHG lithium heparin (12.5 IU) tubes with gel (Terumo Medical Corporation, NJ, USA). The tubes were then centrifuged at 1200G for 10 minutes, followed by collection of plasma into 1.5 ml tubes and storage at -80°C.
[0081] Plasma was analyzed for CBS activity using the radioactivity assay shown in Example 1. CBS enzyme activity of the injected enzyme at the indicated time points is shown in Figure 1a. For the IP and IV routes, peak activity was recorded 1 hour after injection, whereas for the SQ route, activity peaked 4 hours after injection due to slower release from the SQ compartment into the circulation. Interestingly, after 8-10 hours, the activity was comparable for all injection routes, and after 24-48 hours, activity was nearly absent.
[0082] To monitor whether rhCBSΔC clearance from the circulation could contribute to the rapid loss of activity in vivo as shown above, plasma proteins from two representative mice from each group above were separated by electrophoresis, transferred to PVDF membranes, and reacted with anti-human CBS antibodies to follow CBS clearance from the circulation. As shown in Figure 1b, progressive clearance of rhCBSΔC from the circulation occurred as a function of time after injection, with the enzyme becoming undetectable as early as 24 hours after injection. Thus, clearance of rhCBSΔC contributes to the observed rapid loss of activity in vivo.
[0083] To increase the retention time of rhCBSΔC, the enzyme was modified with polyethylene glycol (PEG) molecules (PEGylation), either ME-020MA or GL4-400MA PEG. Activated PEG derivatives were purchased from NOF Corporation (Tokyo, Japan). PEGylation was performed according to the manufacturer's instructions. For example, coupling of PEG maleimide derivatives to SH groups of CBS (5 mg / ml) was performed using 100 mM The reaction was carried out in phosphate buffer pH=6 overnight at 4° C. The molar ratio of PEG molecules to CBS protein was 10:1 or 5:1, depending on the activated PEG derivative.
[0084] To evaluate the activity of PEGylated rhCBSΔC, C57BL / 6J mice were injected with 5 mg / kg body weight of ME020MA- or GL4-400MA-PEGylated rhCBSΔC, or non-PEGylated rhCBSΔC, by SQ route. Each treatment arm consisted of two groups of 5 mice (total of 30 mice) and blood was collected as described above. Plasma was analyzed for CBS activity using the radioactivity assay shown in Example 1. Significant activity was detected for both forms of PEGylated enzyme at 24 and 48 hours after injection, with GL4-400MA PEGylated rhCBSΔC activity peaking at 24 hours, as shown in FIG. 1c. This was in sharp contrast to non-PEGylated rhCBSΔC, which showed low or no activity at these same time points. These results demonstrated that PEGylation of rhCBSΔC enzyme was effective in prolonging its activity both in vitro and in vivo.
[0085] Example 3: Repeated injection regimens with PEGylated rhCBSΔC but not with non-PEGylated rhCBSΔC showed accumulation of CBS activity in vivo The rapid clearance rate of the protein from the circulation can be avoided by increasing the number of injections to maintain a higher plasma concentration. Thus, repeated injection regimens were tested with both non-PEGylated and PEGylated rhCBSΔC. C57BL / 6J mice were injected with 5 mg / kg body weight of non-PEGylated rhCBSΔC (n=5) or GL4-400MA rhCBSΔC (n=5) at 0, 24, and 48 hours (arrows in FIG. 2) and bled at the indicated time points. Plasma was analyzed for CBS activity using the radioactivity assay shown in Example 1. As shown in FIG. 2, repeated injections of the non-PEGylated enzyme did not result in accumulation of enzyme activity in the circulation, resulting in almost no activity 24 hours after each injection. In contrast, activity of the PEGylated enzyme peaked and plateaued after two injections.
[0086] Example 4: A single injection of PEGylated rhCBSΔC lowered homocysteine and increased cystathionine in plasma. The previous examples were performed in wild-type mice and focused on characterizing the clearance and activity of injected rhCBSΔC, as well as comparisons between PEGylated and non-PEGylated enzymes. Once it was established that PEGylation prolongs circulation time, a diverse repertoire of PEGylated CBS enzyme molecules was first tested in wild-type mice and then evaluated in a mouse model of homocystinuria.
[0087] A repertoire of rhCBSΔC enzyme modified with various PEG molecules was tested in wild-type mice to determine the best PEGylation strategy. 27 C57BL / 6J mice were divided into 9 experimental groups (n=3). Each experimental group was injected with 5 mg / kg body weight of rhCBSΔC PEGylated with the PEG molecules shown in FIG. 3 or with non-PEGylated enzyme by SQ route. Blood samples were taken at the time points shown in FIG. 3 and PEGylated rhCBSΔC activity was determined using the radioactivity assay shown in Example 1. Data are shown in FIG. 3A as a histogram with standard deviation (STD) and a scatter plot. In general, PEGylation with higher molecular weight PEGs (GL2800MA, 80 kDa; ME-400MA and GL2-400MA, 40 kDa; and ME200-MA0B, 20 kDa) resulted in greater exposure than that observed following PEGylation with molecules that were less than 20 kDa in size, and PEGylation using chemistry targeted to cysteine residues (designated by "MA" to indicate the use of a maleimide reactive group) generally resulted in greater exposure than that observed following PEGylation utilizing other chemistries.
[0088] Before proceeding with the studies on HO mice, the daily variations in homocysteine, cystathionine, cysteine, and methionine in these mice were assayed to determine the diurnal variations of these amino acids in these animals. Thus, blood from six HO mice was drawn at the time points indicated in FIG. 3B throughout the entire 24-hour cycle, and plasma metabolite levels were determined for each indicated time point. As shown in FIG. 3B, the levels of cystathionine and cysteine were fairly constant throughout the 24-hour cycle. Homocysteine and methionine levels tended to decline from 7:00 a.m. to late morning to early afternoon. This was consistent for animals that fed at night and lacked the ability to metabolize homocysteine via the sulfur transfer pathway. Thus, all injections and blood draws were performed at 15:00 (3 PM), when Hcy levels were at their lowest, to determine whether treatment resulted in further reductions in Hcy and other metabolites.
[0089] The molecular weight and specific activity (SA) of PEGylated rhCBSΔC are central properties for characterization. After PEGylation with ME-400MA (lane 1, FIG. 3C), GL4-400MA (lane 2) or ME-200MA0B (lane 3), the products were separated by electrophoresis on a 12% SDS-PAGE gel and compared with the non-PEGylated enzyme (lane 4). The resulting gel was stained with Coomassie blue. The SA (U / mg) of each of the PEGylated and non-PEGylated rhCBSΔC is shown in FIG. 3C in the attached table. As shown, PEGylation had no significant effect on the SA value and the enzyme remained as active as before PEGylation. According to the apparent molecular weight, PEGylation of rhCBSΔC under the conditions used in this experiment resulted in di-PEGylated and tri-PEGylated rhCBSΔC.
[0090] The overall objective of the experiments described herein was to evaluate the pharmacodynamic parameters of administered PEGylated rhCBSΔC. Special emphasis was placed on lowering plasma homocysteine and increasing plasma cystathionine in an animal model of CBS-deficiency homocystinuria. HO mice fed normal mouse chow were selected as a model system to test this type of enzyme replacement therapy (ERT). HO mice were injected once with rhCBSΔC PEGylated with PEG molecules (GL4-400MA, ME-400MA, ME-200MA0B) at time 0 and blood was collected at time 0 (pre-injection), 24 hours, 48 hours and 72 hours. Plasma homocysteine (Figure 3D) and cystathionine (Figure 3E) levels for each of the above groups (n=5-6) are shown. As shown in Figure 3D, homocysteine levels were significantly reduced for each PEGylated form used, and cystathionine levels (Figure 3E) were increased approximately 6- to 7-fold compared to time 0. Thus, administration of PEGylated rhCBSΔC was found to have a significant and positive impact on homocysteine and cystathionine levels in vivo.
[0091] Example 5: Repeated injections of PEGylated rhCBSΔC significantly affect homocysteine and cystathionine plasma levels and restore normal cysteine levels. A repeated injection regimen with washout period comparing non-PEGylated and PEGylated rhCBSΔC for their ability to lower and maintain low levels of homocysteine, as well as to increase cystathionine and cysteine levels, was performed as follows: Six HO mice were injected with rhCBSΔC PEGylated with GL4-400MA PEG on days 0, 1, 2, 3, and 4 (arrows, FIG. 4), followed by a washout period of 10 days, and then injected again on days 14, 15, 16, 17, and 18. Plasma samples were taken at the time points indicated in FIG. 4 (always before injection). For comparison, the same injection regimen was also performed on five HO mice injected with non-PEGylated enzyme. Plasma metabolite levels were measured using Stable-Isotope-Dilution Liquid Chromatography-Mass Spectroscopy (SLS-MS) as described in Example 1e. Spectrometry. Plasma concentrations of homocysteine (results shown in FIG. 4a) and cystathionine (FIG. 4b) for each mouse are shown. The average values of homocysteine and cystathionine for each experimental group are also shown (in FIG. 4c). As shown in FIGS. 4a-4c, the average homocysteine concentration dropped from 182 μM to 38 μM at 48 hours and remained low throughout the week. Cystathionine reached a concentration of 42 μM at 48 hours from an initial 4.7 μM at time 0 and remained high during the first week. During the withdrawal period, the metabolites returned to their initial values. Subsequent CBS injections again resulted in a sharp drop in homocysteine levels and an increase in cystathionine levels. Cessation of treatment then again resulted in a return of these parameters to untreated levels.
[0092] The effect of PEGylated rhCBSΔC on plasma homocysteine levels was also determined, as shown in Figure 4d as a percentage at time 0, compared to non-PEGylated rhCBSΔC. Figure 4d illustrates that in contrast to PEGylated rhCBSΔC, the non-PEGylated enzyme had no apparent effect on homocysteine concentrations when blood samples were taken 24 hours or more after injection. This is consistent with the results shown in Examples 2 and 3, which show that the non-PEGylated enzyme was rapidly cleared from the circulation and had no significant activity 24 and 48 hours after injection.
[0093] The effect of PEGylated rhCBSΔC on plasma cysteine levels compared to non-PEGylated rhCBSΔC was also determined using the same experimental method, As shown in Figure 4E, cysteine levels normalized during the injection period of PEGylated enzyme (2-fold compared to time 0), whereas no change in cysteine levels was observed with non-PEGylated enzyme.
[0094] These results indicated that PEGylated rhCBSΔC enzyme administered SQ to HO mice had a significant positive effect on homocysteine and cystathionine concentrations, while restoring cysteine levels to their normal values, the latter experimental result being an indication that the intracellular sulfur transfer pathway was activated after administration of rhCBSΔC.
[0095] Example 6: Variability in the degree of aggregation of human truncated CBS preparations (rhCBSΔC) Native PAGE gels (4-15%, i.e., without the addition of denaturing agents such as sodium dodecyl sulfate) were performed with different batches of rhCBSΔC (112, 13, 7, 27 and 28). The results shown in FIG. 5A illustrate that the different preparations have different ratios of tetramer (T) and dimer (D), as well as higher forms of aggregated CBS. CBS activity in the gel (FIG. 5B) was determined (by activity staining) in native polyacrylamide gels by performing electrophoresis on protein samples at 4° C. The gels were then submerged in activity staining solution (see Table A) and incubated at 37° C. for about 15 minutes. After about 15 minutes, depending on the amount loaded, a dark gray band (about 45 kDa dimer of the 1-413 CBS species) appeared. After longer periods; up to 1 hour or overnight at room temperature, the tetramer became visible. Analysis of native gels with this in-gel activity method confirms that the tetramer (T), dimer (D), and other higher aggregated forms of rhCBSΔC bands appearing in batches 112 and 28 in FIG. 5A were CBS-associated, as illustrated in FIG. 5B.
[0096] [Table 2] SDS PAGE analysis of batches 28 and 112 and their PEGylated products showed that PEGylation of rhCBSΔC batches with ME-200MA0B showed varying ratios between the two PEGylated bands (P) formed after PEGylation (see FIG. 5C). Thus, a means to reduce aggregation and increase reproducibility was sought.
[0097] Example 7: Only the human C15S mutant CBS forms dimers Since the cysteine (at position 15 of rhCBSΔC) does not couple, it was considered a possible factor leading to aggregate formation. Therefore, a new recombinant plasmid was prepared to generate rhCBSΔC mutant protein (referred to herein as C15S). The same strategy used in Example 1b to generate rhCBSΔC was used to generate the C15S mutant CBS enzyme (T→A nucleotide mutation) by using the following primers:
[0098] [ka] The entire nucleotide sequence of the C15S mutant CBS truncated enzyme (SEQ ID NO: 14) was verified by nucleotide sequencing. The same method described in Example 1 for recombinant human CBS truncated was used for expression and isolation of the C15S mutant CBS enzyme.
[0099] Native PAGE of the isolated C15S CBS enzyme demonstrated that the C15S CBS exists only as a dimer, unlike the results obtained for recombinant human truncated CBS (rhCBSΔC), which formed dimers (D) and tetramers (T), as well as higher oligomeric forms (see FIG. 6A). Multiple batches of C15S mutant CBS (51, 60, and 73) and recombinant human doubly truncated (batch RC-2-76) demonstrated that both formed only dimers, in contrast to the recombinant human truncated CBS (rhCBSΔC) (see FIG. 6B). PEGylation of C15S with ME-200MA0B produced uniform and reproducible bands with similar ratios between the PEGylated bands. Denaturing SDS PAGE showed that C15S gave rise to a reproducible PEGylation pattern similar to recombinant human doubly truncated (batch RC-2-76), both distinct from the pattern obtained using recombinant human truncated CBS (rhCBSΔC) (Figure 6C), which was also comparable to Figure 5C showing a non-reproducible PEGylation pattern with rhCBSΔC.
[0100] HPLC size-exclusion chromatography of CBS preparations was performed. Both recombinant human truncated CBS (rhCBSΔC) (Figure 7A) and the C15S mutant (Figure 7B) were separated on a Yarra SEC-3000, 300 × 7.8 mm size-exclusion column (Phenomenex, CA, USA). The column was calibrated and loaded with 100 mM sodium phosphate. The mixture was run at room temperature at pH=6.8 with a flow rate of 1 ml / min. Figure 7 shows size exclusion chromatography (SEC) analysis of rhCBSΔC (Figure 7A) and the C15S mutant (Figure 7B). These analyses gave a reproducible single peak from five different batches, providing additional evidence that the C15S mutant CBS existed only as a dimer (see Figure 7B). For comparison, note the six different patterns of rhCBSΔC in Figure 7A and the single peak of the C15S mutant CBS in Figure 7B.
[0101] Example 8: Continuous administration of PEGylated C15S for 20 days resulted in a reduction in plasma homocysteine in two HO mice. ALZET® osmotic pumps allowed for constant and controlled delivery of C15S enzyme over an extended period of time. The C15S CBS enzyme was administered using an ALZET® pump (Micro-osmotic ALZET® Pump, Model 1002. Lot 10268-12) to continuously deliver C15S CBS enzyme to mice instead of repeated subcutaneous injections. In these experiments, the average pump delivery rate was 0.21 μl / hour; the average fill volume was 106.6 μl; the pump was loaded with approximately 106 μl of PEGylated C15S CBS enzyme at a concentration of 26.2 μg / μl. Continuous administration of C15S CBS over a 20-day period in two HO mice produced an initial significant and then sustained reduction in plasma homocysteine (see FIG. 8).
[0102] For pre- and post-operative pain relief, animals were given TYLENOL® (2 mg / ml) ad libitum in water bottles for 48 hours before and after ALZET® pump implantation surgery. Additionally, animals were given Carprofen 5 mg / kg subcutaneously every 24 hours for 48 hours post-operatively.
[0103] For animal anesthesia and surgery, isoflurane was administered by inhalation. Mice were induced with 5% isoflurane and maintained at 2-3%. While the mice were anesthetized, they each received a medical grade ALZET® osmotic pump implanted under sterile conditions in a Biological Safety Cabinet. Pumps were implanted subcutaneously in the ventral loose skin area of the neck. Prior to implanting the pumps, the mice were shaved and the skin area was prepared with BETADINE®. Pump implantation required creating a small surgical incision (5 mm) with sterile scissors. The incision was closed with wound clips. Clips were removed after one week when the skin had fully healed. Just prior to pump implantation and at the times indicated in Figure 8, blood samples were taken to measure homocysteine levels. The results show that this mode of administration reduces homocysteine levels in a manner similar to that achieved by daily rhCBSΔC administration. Similar experiments performed using non-PEGylated C15S mutant CBS did not result in a clear reduction in Hcy plasma levels (results not shown).
[0104] Example 9: Comparison of three PEGylated truncated human CBS enzymes FIG. 9 is a bar graph showing the results of an experiment in which HO mice were injected with ME-200MA0B PEGylated rhCBSΔC, C15S mutant (C15S) and double truncated construct (double truncated) at a single dose (7.5 mg / kg) at time 0. Mice were bled at time 0 (pre-injection), 24 hours, 48 hours and 72 hours after injection. Plasma homocysteine levels for each of the groups (n=5-6) are shown. The results show that all three enzyme forms result in a comparable reduction in Hcy plasma concentrations.
[0105] [Table 3-1]
[0106] [Table 3-2]
[0107] [Table 3-3]
[0108] [Table 3-4] While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent that modifications and variations are contemplated without departing from the scope of the invention as defined in the appended claims. More specifically, although several aspects of the invention are identified herein as particularly advantageous, it is contemplated that the invention will not necessarily be limited to these particular aspects of the invention.
Claims
1. 1. A human truncated cystathionine beta-synthase (htCBS) mutant polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:3 and having a C15S mutation compared to SEQ ID NO:3, wherein the htCBS mutant polypeptide is covalently linked to at least one polyethylene glycol (PEG) molecule, wherein the at least one PEG molecule is an NHS ester activated PEG molecule and has a molecular weight of 20 kDa or greater.
2. 2. The htCBS mutant polypeptide of claim 1, wherein the htCBS mutant polypeptide is isolated from E. coli transfected with an expression vector encoding the nucleic acid sequence of SEQ ID NO:
14.
3. 3. A pharmaceutical composition comprising an htCBS variant polypeptide according to claim 1 or 2 and a pharma- ceutically acceptable carrier, diluent or excipient.
4. 4. The pharmaceutical composition of claim 3 for use in treating homocystinuria in a subject.
5. 4. The pharmaceutical composition of claim 3 for use in treating a disease, disorder, or condition associated with elevated homocysteine in a subject.
6. 6. The pharmaceutical composition for use according to claim 4 or 5, for administering said htCBS variant polypeptide to said subject at a dose of from 0.1 mg / kg to 20 mg / kg.
7. The pharmaceutical composition for use according to any one of claims 4 to 6, wherein the subject is also administered anethole dithiolethione or betaine.
8. The pharmaceutical composition for use according to any one of claims 4 to 7, wherein the subject is also receiving an anticoagulant or a statin.
9. The pharmaceutical composition for use according to any one of claims 4 to 8, wherein the subject is on a mild protein restricted diet.
Citation Information
Patent Citations
HUMAN CYSTATHIONINE beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
WO2003106971A2
